Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

='External Link';s.eVar3=s.prop5;s.prop15='79490252';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.anadyspharma.com/">www.anadyspharma.com. A telephone replay with slides will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 75270153. The webcast and telephone replay will be available through December 31, 2009.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the expected timing for enrolling the next cohort in the ANA598 Phase II study and for receiving 12 week data from the 200 mg bid cohort and 4 and 12 week data from the 400 mg bid cohort; (ii) the prospects of ANA598 being able to contribute to long-term treatment outcome as measured by SVR and the hope that ANA598 will be established as the leading non-nucleoside in HCV, suitable for combination with current SOC as well as with other direct antivirals currently in development; (iii) the ability for patients to achieve EVR and SVR in the ANA598 Phase II study; and (iv) assessments of the safety and tolerability profile of ANA598 based on the interim 4 week analysis. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues or will continue to have favorable results as the Phase II trial progresses. In addition, Anadys' results may be affected by competition from other biotechno
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , August 28, 2014 ... Market Research "Radiofrequency Identification (RFID) Market (Tags, Readers, Middleware, ... Growth, Trends and Forecast, 2014 - 2020" the global ... billion in 2013 and is expected to grow at ... reach an estimated value of USD 5.3 billion in ...
(Date:8/28/2014)... 28, 2014   Venaxis, Inc.  (Nasdaq:  APPY), an ... FDA clearance for and commercializing its CE Marked ... in identifying children, adolescent, and young adult patients in ... appendicitis, today announced it will present at three upcoming ... Annual Global Investment Conference being held in ...
(Date:8/28/2014)... 2014 Telik, Inc. (OTCQB: TELK), a ... with MabVax Therapeutics, Inc. on July 8, 2014, ... to the development of its lead antibody program ... the Company,s internally developed antibody discovery platform.  These ... antibody based therapeutic and diagnostic products based on ...
Breaking Medicine Technology:Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
... traits contribute to risk, of skin cancer; findings will ... May 18 In two papers published,today, deCODE scientists ... the company,s recent findings in the genetics of pigmentation,traits ... of these,common variants also confer risk of two types ...
... Annual Meeting Will Further Demonstrate, the Strength ... CAMBRIDGE, Mass., May 16 Millennium Pharmaceuticals,The Takeda Oncology ... are scheduled to be featured at the 2008 American ... May 30 -,June 3, 2008. The data will highlight ...
Cached Medicine Technology:deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 2deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 3deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8
(Date:8/28/2014)... 28, 2014 Home Care Assistance ... for seniors, is proud to welcome Carrie Rose as ... Home Care Assistance, Carrie worked as a caregiver in ... Certified Nursing Assistant in skilled nursing facilities for several ... a trainer with the State of Arizona in the ...
(Date:8/28/2014)... have been adopted by most health agencies to deal ... unnecessary, and may heighten panic and fear among the ... published in The Lancet , and written by ... in Spain, and colleagues. , Ebola virus is ... faeces and other secretions, both direct and indirect, from ...
(Date:8/28/2014)... become increasingly about datahow to gather it, organize ... databases to analyze and share data lies at ... collection, classification, storage, and analysis of biochemical and ... and methods used in bioinformatics have been instrumental ... genetics and genomics. But, in the plant sciences, ...
(Date:8/28/2014)... Worth, FL (PRWEB) August 28, 2014 Following ... on July 21, the FDA issued a warning ... the word about this harmful substance that is readily available ... , In May, high school senior Logan Stiner died from ... investigation of the substance, leading the FDA to issue a ...
(Date:8/28/2014)... researchers place glue directly on the nerve stumps, but ... and allows glue to easily invade the nerve ends. ... to insert the nerve ends into the conduit because ... Xiangdang Liang and co-workers from the General Hospital of ... technique and defined the best parameters for its use ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance Expands Staff to Meet Growing Demand for In-Home Care Services in Scottsdale 2Health News:Home Care Assistance Expands Staff to Meet Growing Demand for In-Home Care Services in Scottsdale 3Health News:The Lancet: Respiratory infection controls being used for ebola patients are unnecessary and may contribute to public panic 2Health News:Together, humans and computers can figure out the plant world 2Health News:Together, humans and computers can figure out the plant world 3Health News:FDA Issues Safety Advisory for Caffeine Powders 2
... Presents Study at International Society of Cellular Therapy ... Cells for Possible Utilization in TransplantationOLDSMAR, Fla., May ... announced results of a new study showing that ... cells from umbilical cord blood expands the number ...
... N.Y., May 5 Nutrition 21, Inc. (Nasdaq: ... help consumers manage blood sugar levels, improve cardiovascular health, enhance ... - prior to the opening of the market - on ... year 2009, ended March 31, 2009. The Company has scheduled ...
... 5 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex" or the ... independent American,provider of Western healthcare products and services ... the Company is scheduled to participate in the,Oppenheimer ... 19-21, 2009, at,300 Madison Avenue in New York ...
... Assists Physicians In Identifying Recurrence Risk and the Need ... Clarient, Inc. (Nasdaq: CLRT ... resource for pathologists, oncologists and the pharmaceutical industry, today ... test that helps physicians identify the probability of a ...
... It,s official...Curamin is the natural products industry,s Best ... number-one pain-relieving product, is slated to receive a ... magazine in its upcoming June issue. The ... based on a nationwide survey of health food ...
... medical supplies on a regular basis can save even more with ... many struggle with rising medical costs, the MSD Club membership will ... incontinence and other disposable medical supplies. , ... (PRWEB) ...
Cached Medicine News:Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 2Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 3Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 4Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 5Health News:Nutrition 21 to Report Third Quarter Fiscal Year 2009 Financial Results on Tuesday, May 12, 2009 2Health News:Chindex International, Inc. Announces May Conference Participation 2Health News:Clarient Launches New Breast Cancer Test 2Health News:Clarient Launches New Breast Cancer Test 3Health News:Clarient Launches New Breast Cancer Test 4Health News:Clarient Launches New Breast Cancer Test 5Health News:Clarient Launches New Breast Cancer Test 6Health News:Curamin Voted Best New Natural Remedy in the Country 2Health News:TheMedicalSupplyDepot.com Announces New Discount Medical Supplies MSD Club 2
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Sheath Introducer featuring patented SLIX Valve, rotating collar, kink-resistant cannula and atraumatic tip transitions....
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3....
Medicine Products: